Flexion Therapeutics Reports Third-Quarter 2014 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Flexion Therapeutics Reports Third-Quarter 2014 Financial Results

Recent Highlights

  • Following meeting with U.S. Food & Drug Administration (FDA), announced plans to accelerate initiation of a Phase 3 clinical trial for FX006
  • Bolstered intellectual property (IP) protection for FX006
  • Achieved progress in addressing questions related to FDA's clinical hold of FX006

BURLINGTON, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced key operational highlights and financial results for the third quarter ended September 30, 2014.

"During the third quarter of 2014, Flexion had several important events occur related to our lead clinical candidate FX006. We had two achievements that enhanced IP protection for FX006: we were issued a composition of matter patent from the U.S. Patent and Trademark Office (U.S. PTO) and we acquired an exclusive license regarding microsphere manufacturing technologies from Southwest Research Institute (SwRI®). On the regulatory front for FX006, we updated our clinical timing and plans for a Phase 3 trial following a meeting with the FDA, and have made significant progress in addressing the agency's clinical hold, which was initiated in September," said Michael Clayman, M.D., Flexion Therapeutics President and Chief Executive Officer.

Third-Quarter Financial Results

The company reported a net loss of $7.0 million for the three months ended September 30, 2014, compared to a net loss of $5.1 million for the same period in 2013.

Research and development expenses increased to $4.7 million for the three months ended September 30, 2014, compared to $2.6 million for the same period in 2013, due to costs related to the FX006 pivotal Phase 2b dose confirmatory trial of $2.3 million and higher salary and employee related costs due to greater headcount levels of $0.2 million.

General and administrative expenses decreased to $2.3 million for the three months ended September 30, 2014, as compared to $2.4 million for the same period in 2013, due primarily to decreased professional service fees.

For the nine months ended September 30, 2014, the company reported a net loss of $19.5 million, compared to a net loss of $14.5 million for the same period in 2013.

Research and development expenses increased to $12.4 million for the nine months ended September 30, 2014 compared to $8.8 million for the same period in 2013, due to FX006 program expenses related to the pivotal Phase 2b dose confirmatory trial and manufacturing expenses associated with clinical trial supplies. In addition, increases in salary and other employee related costs, including stock compensation expense, contributed to the higher spending level.

General and administrative expenses increased to $6.8 million for the nine months ended September 30, 2014 compared to $5.4 million for the same period in 2013, due to higher salary and related employee costs, including stock compensation expense, as a result of additional headcount. In addition, increases in legal, professional fees and insurance costs associated with being a public company contributed to the higher spending level.

As of September 30, 2014, the company had $66.6 million in cash and cash equivalents and marketable securities compared to $16.4 million as of December 31, 2013.

Third-Quarter and Recent Corporate Highlights:

  • Intellectual Property Advancements for FX006:
    • In September, we announced issuance of a U.S. composition of matter patent from the U.S. PTO, which underpins the formulation technology for FX006 and has a patent term lasting into 2031, thereby providing a critical foundation for eventually commercializing the product.
    • In July, we announced the execution of an exclusive worldwide licensing agreement with SwRI to utilize proprietary microsphere manufacturing technologies for production of Flexion's sustained-release drug candidates, including lead candidate FX006. The exclusive license adds another layer of IP protection for FX006 and provides for an expanded field of use in a variety of musculoskeletal disorders where sustained-release technology could be useful for patients.
       
  • Regulatory Updates
    • Following a meeting with the FDA to review the clinical development program for FX006, we announced in early September plans to accelerate the initiation of a Phase 3 clinical trial for FX006. In the meeting with the agency, FDA representatives had communicated that they will consider the company's ongoing placebo-controlled, pivotal Phase 2b trial of FX006 as one of two key efficacy trials required for registration of a single-dose administration for FX006. In addition, the FDA provided guidance that a second placebo-controlled pivotal trial would be sufficient to support the filing of a new drug application (NDA). The FDA also communicated that the approval of FX006 for single-dose administration will not require data from a repeat-dose safety trial, which enabled the most significant change from the company's prior clinical development plan.
    • Later in September, we were informed by the agency that it had placed a clinical hold on patient enrollment and dosing in the ongoing pivotal Phase 2b clinical trial evaluating FX006 in patients with OA of the knee. Since that time, we have made significant progress in addressing the hold by performing various required sterility and bio-burden tests to assess the potential of drug contamination. In addition, our quality assurance team has conducted audits of the clinical site and our manufacturing, testing and contract sterilization vendors, to evaluate their process and procedures surrounding sterilization technique.    

Conference Call

At 4:30 p.m. ET today, Flexion's management will host a conference call and webcast to review the Company's third quarter financial results and provide a general business update. The dial-in number for the conference call is toll-free (855) 770-0022 for domestic participants and (908) 982-4677 for international participants. A live webcast of the conference call can also be accessed through the " Investors " tab on the Flexion Therapeutics website at www.flexiontherapeutics.com . A webcast replay will be available online after the call.

About Flexion Therapeutics

Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead program, FX006, is an intra-articular sustained-release steroid in development for patients with moderate to severe OA pain. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.

Forward-Looking Statements

Statements in this press release regarding matters that are not historical facts, including statements relating to the future of Flexion, its ongoing development of its product candidates, the potential duration and impact of patent protection for FX006, Flexion's plans to resume its pivotal Phase 2b trial of FX006 and initiate a Phase 3 clinical trial of FX006, anticipated clinical and other milestones (including the timing of such milestones), and the potential role of FX006 in the treatment of patients with OA of the knee and other musculoskeletal disorders are forward-looking statements. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks associated with the process of discovering, developing and obtaining regulatory approval for drugs that are safe and effective for use as human therapeutics, whether the company's patents will be held valid and enforceable, the fact that Flexion relies on third parties to manufacture and conduct the clinical trials of its product candidates, which could delay or limit their future development or regulatory approval, the possibility that future trial results may not be consistent with past results, the fact that Flexion will require additional capital, including prior to completing Phase 3 development of, filing for regulatory approval for, or commercializing, FX006 or any of its other product candidates and may be unable to obtain such additional capital in sufficient amounts or on terms acceptable to it, and other risks and uncertainties described in Flexion's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Flexion's Annual Report on Form 10-K for the year ended December 31, 2013 and subsequent filings with the SEC. You are encouraged to read Flexion's filings with the SEC, available at www.sec.gov , for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of the statements.

FLEXION THERAPEUTICS
CONDENSED STATEMENT OF OPERATIONS
(in thousands, except for per share information)
         
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2014 2013 2014 2013
Revenue $  -- $ -- $  -- $ --
         
Operating expenses:        
         
Research and development 4,658 2,570 12,424 8,825
         
General and administrative 2,304 2,420 6,822 5,363
         
Total expenses 6,962 4,990 19,246 14,188
         
Loss from operations (6,962) (4,990) (19,246) (14,188)
         
Interest income (expense), net 56 (75) 4 (116)
         
Other income (expense) (130) (35) (266) (192)
         
Loss from operations before income tax (7,036) (5,100) (19,508) (14,496)
         
Net loss (7,036) (5,100) (19,508) (14,496)
         
Basic and diluted net loss per share $ (0.45) $ (6.46) $ (1.50) $ (18.37)
         
Basic and diluted weighted average number of common shares outstanding 15,625 1 789 13,008 1 789
         
1 Note that the issuance of additional common stock and the conversion of preferred stock in connection with the Company's IPO in February 2014 resulted in a significant increase in the Company's weighted average shares outstanding that is expected to impact the year-over-year comparability of the Company's earnings/loss per share in 2014.
 
FLEXION THERAPEUTICS
SELECTED BALANCE SHEET DATA
(in thousands)
     
  September 30, December 31,
  2014 2013
     
Cash and cash equivalents $14,365 $16,188
Marketable securities 52,224 250
Total current assets 67,299 16,620
Working capital 61,104 11,584
Total assets 68,125 18,776
Total notes payable 4,082 5,047
Convertible preferred stock (Series A and B)  --  74,806
Total stockholders' equity (deficit) 59,791 (64,704)

Media Contact Jamie Lacey-Moreira PressComm PR, LLC T: 410-299-3310 Corporate Contact Lisa Davidson, MBA Vice President, Finance and Administration Flexion Therapeutics, Inc. T: 781-305-7765

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 137

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 58

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 58

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 133

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 58

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 68

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 159

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 62

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Tim Hortons Bets on ELF Cheer for U.S. Holiday Visits

Updated Category News Views 35

Nothing says holiday restaurant marketing quite like putting spaghetti-shaped whipped topping on hot chocolate and trusting a 2003 movie to do the selling. Tim Hortons is rolling out an ELF-inspired menu at participating U.S. locations starting November 18, 2026, pairing the chain with Warner Bros. Consumer Products and mining Buddy the Elf's sugar-fueled world for a...

Continue Reading

Top 5 Most Recently Viewed Articles

T&T Supermarkets Expands Presence with New Store Opening

Updated Category News Views 466

T&T Supermarkets Unveils Plans for a Major New Store T&T Supermarket Inc., Canada's largest Asian grocery retailer, is excited to share plans for their newest store in California, which will be located at Crossroads Marketplace in Chino Hills. This store will span an impressive 61,000 square feet, providing ample space for a wide variety of products and services to meet...

Continue Reading
Autohome Inc. Unveils its Comprehensive 2024 ESG Report

Updated Category News Views 268

Autohome Inc. Releases 2024 ESG Report Autohome Inc. (NYSE: ATHM) has shared its 2024 Environmental, Social, and Governance (ESG) report. This document emphasizes the firm's commitment to sustainable practices and highlights their ongoing journey towards eco-friendly solutions within the automobile sector. Insights from the ESG Report The report details the extensive ESG...

Continue Reading
Nintendo and The Pokemon Company Pursue Legal Action Against Palworld

Updated Category News Views 87

Nintendo and The Pokemon Company Take Legal Action Nintendo and The Pokemon Company have officially initiated a patent infringement lawsuit against the creators of the popular survival adventure game, "Palworld." This development has caught the attention of both gamers and industry experts alike. Details of the Lawsuit Reports indicate that the lawsuit was filed on...

Continue Reading
NYCM Insurance Achieves Elite Winner Status for Wellness

Updated Category News Views 118

NYCM Insurance Celebrated for Wellness Excellence NYCM Insurance proudly announces its recognition as an "Elite Winner" among the Nation's Best and Brightest in Wellness. This marks an outstanding milestone for the company, achieving the accolade for the twelfth consecutive year, a testament to their dedication to enhancing employee wellness. Commitment to Employee...

Continue Reading
Antonio Filosa Leads Stellantis with Newly Formed Team

Updated Category News Views 284

New Leadership Structure at Stellantis Under Antonio Filosa Today marks a significant milestone for Stellantis N.V. as Antonio Filosa steps into the role of Chief Executive Officer. Alongside this transition, he has unveiled an exciting new leadership team, showcasing a strong lineup of industry veterans and decision-makers from across Stellantis’ diverse operations...

Continue Reading